Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in I… Read more
Deciphera Pharmaceuticals Inc (D05) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2024: -0.173x
Based on the latest financial reports, Deciphera Pharmaceuticals Inc (D05) has a cash flow conversion efficiency ratio of -0.173x as of March 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-54.59 Million) by net assets (€316.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Deciphera Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2016–2023)
This chart illustrates how Deciphera Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Deciphera Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Deciphera Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Capri Holdings Ltd
NYSE:CPRI
|
1.874x |
|
Keda Clean Energy Co Ltd
SHG:600499
|
0.094x |
|
Page Industries Limited
NSE:PAGEIND
|
0.356x |
|
Adata Technology Co Ltd
TWO:3260
|
-0.077x |
|
Oberbank AG
VI:OBS
|
-0.099x |
|
Indra Sistemas S.A
OTCGREY:ISMAF
|
0.005x |
|
Customers Bancorp Inc
NYSE:CUBI
|
0.057x |
|
WuXi XDC Cayman Inc.
F:L74
|
N/A |
Annual Cash Flow Conversion Efficiency for Deciphera Pharmaceuticals Inc (2016–2023)
The table below shows the annual cash flow conversion efficiency of Deciphera Pharmaceuticals Inc from 2016 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €350.92 Million | €-153.05 Million | -0.436x | +2.51% |
| 2022-12-31 | €341.69 Million | €-152.86 Million | -0.447x | +43.39% |
| 2021-12-31 | €304.72 Million | €-240.82 Million | -0.790x | -79.27% |
| 2020-12-31 | €543.68 Million | €-239.68 Million | -0.441x | -61.37% |
| 2019-12-31 | €546.47 Million | €-149.30 Million | -0.273x | +11.86% |
| 2018-12-31 | €279.98 Million | €-86.78 Million | -0.310x | -55.37% |
| 2017-12-31 | €183.97 Million | €-36.70 Million | -0.199x | -220.75% |
| 2016-12-31 | €-139.76 Million | €-23.09 Million | 0.165x | -- |